...
首页> 外文期刊>European review for medical and pharmacological sciences. >Analysis of circulating long non-coding RNA UCA1 as potential biomarkers for diagnosis and prognosis of osteosarcoma
【24h】

Analysis of circulating long non-coding RNA UCA1 as potential biomarkers for diagnosis and prognosis of osteosarcoma

机译:循环长非编码RNA UCA1作为骨肉瘤诊断和预后的潜在生物标志物分析

获取原文

摘要

OBJECTIVE: The aim of this investigation was to examine the potential usefulness of long non-coding RNA UCA1 (UCA1) as a biomarker for diagnosis and prognosis in osteosarcoma. PATIENTS AND METHODS: The expression level of UCA1 was determined using TaqMan real-time PCR in human osteosarcoma tissues and patients’ sera. Next, we investigated to clarify the relationship of UCA1 with clinicopathological features. The receiver operating characteristic (ROC) curve was performed to estimate the diagnostic value of UCA1. Finally, the prognosis of patients with osteosarcoma was assessed by Kaplan-Meier method and Cox proportional hazards model. RESULTS: We observed that UCA1 was significantly increased in osteosarcoma tissue compared with normal bone tissue (p<0.001) and the serum expression of UCA1 was significantly higher in patients with osteosarcoma than that in healthy controls (p<0.01). Up-regulation of UCA1 was correlated with clinical stage (p=0.001) and metastasis (p=0.007). Furthermore, serum UCA1 levels were observed to be robust in differentiating osteosarcoma patients from control subjects [area under the curve (AUC) = 0.831; 95% confidence interval (CI)= 0.746 to 0.916]. Kaplan-Meier analysis showed that that high UCA1 expression level was associated with poorer overall survival (p<0.001) and disease-free survival (p<0.001). Finally, Cox regression analyses showed that UCA1 expression might be an independent prognostic parameter to predict poor prognosis. CONCLUSIONS: Our study firstly showed that UCA1 could be a specific and noninvasive candidate biomarker for the diagnosis and prognosis of UCA1.
机译:目的:本研究的目的是检查长的非编码RNA UCA1(UCA1)作为骨肉瘤诊断和预后的生物标志物的潜在用途。患者和方法:使用TaqMan实时PCR检测UCA1在人骨肉瘤组织和患者血清中的表达水平。接下来,我们进行研究以阐明UCA1与临床病理特征的关系。执行接收器工作特性(ROC)曲线以估算UCA1的诊断值。最后,通过Kaplan-Meier方法和Cox比例风险模型评估骨肉瘤患者的预后。结果:我们观察到骨肉瘤组织中UCA1的表达明显高于正常骨组织(p <0.001),骨肉瘤患者中UCA1的血清表达明显高于健康对照组(p <0.01)。 UCA1的上调与临床分期(p = 0.001)和转移(p = 0.007)相关。此外,在将骨肉瘤患者与对照对象区分开来时,观察到血清UCA1水平很强[曲线下面积(AUC)= 0.831; 95%置信区间(CI)= 0.746至0.916]。 Kaplan-Meier分析表明,高UCA1表达水平与较差的总生存期(p <0.001)和无病生存期(p <0.001)相关。最后,Cox回归分析表明UCA1表达可能是预测不良预后的独立预后参数。结论:我们的研究首先表明,UCA1可能是UCA1的诊断和预后的特异性和非侵入性候选生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号